ClinicalTrials.gg
Sign In

Conjunctivitis, Allergic clinical trials

The registry lists 210 studies for Conjunctivitis, Allergic across more than 10 countries. 18 are recruiting or about to start. 173 of them are mainly about Conjunctivitis, Allergic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Conjunctivitis, Allergic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
157
Status unknown
16
Recruiting
12
Terminated
9
Withdrawn
6
Not yet recruiting
5

Phase

Phase 3
72
Phase 2
51
Phase 4
42
Phase 1
12

Where

United States
94
Canada
14
Japan
11
Italy
11
France
10
Germany
9

Who runs them

Alcon Research (21) · Bausch & Lomb Incorporated (17) · Vistakon Pharmaceuticals (9) · ORA, Inc. (9) · Allergan (9) · Aldeyra Therapeutics, Inc. (7) · Regeneron Pharmaceuticals (6) · Aciex Therapeutics, Inc. (6)

What is being tested here

Drugs under test in Conjunctivitis, Allergic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
TL-925304
Tacrolimus137
Probiotic101
Cenegermin111
Olopatadine0726
Alcaftadine0510
Bepotastine besilate037
Reproxalap036
Ketotifen035
Loteprednol Etabonate005

Drug classes tested here Calcineurin inhibitors 1 open · Antihistamines 59 · Corticosteroids 10

Coming up

3phase 3 studies under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger. 4 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (17%) take healthy volunteers.

Recruiting studies that take each age, of 12
AgeWomenMen
104 (33%)4 (33%)
1811 (92%)11 (92%)
3011 (92%)11 (92%)
4011 (92%)11 (92%)
5010 (83%)10 (83%)
659 (75%)9 (75%)
758 (67%)8 (67%)
858 (67%)8 (67%)

Across all 210 studies, recruiting or not: 25% stop at 75 or younger and 24% at 65; 46% take children; 0% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Conjunctivitis, Allergic studies take

Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 36 mo4–14 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 210. Browse all 210 → or search them.